β- and γ-diketones and γ-hydroxyketones as WNT/ β-catenin signaling pathway activators
申请人:Samumed, LLC
公开号:US08629176B1
公开(公告)日:2014-01-14
The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
本发明揭示了β-二酮,γ-二酮或γ-羟基酮或其类似物,可以激活Wnt/β-连环蛋白信号传导,因此可以治疗或预防与信号转导相关的疾病,如骨质疏松症和骨关节病;成骨不全症,骨缺陷,骨折,牙周病,耳硬化症,创伤愈合,颅颜部缺陷,骨溶解性肿瘤性疾病,与中枢神经系统的分化和发育相关的创伤性脑损伤,包括帕金森病,中风,缺血性脑疾病,癫痫,阿尔茨海默病,抑郁症,躁郁症,精神分裂症;眼部疾病,如老年性黄斑变性,糖尿病性黄斑水肿或色素性视网膜炎,以及与干细胞分化和生长相关的疾病,包括脱发,造血相关疾病和组织再生相关疾病。